MIMEDX GROUP, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.15 USD | +0.42% |
|
-7.74% | -18.47% |
| Apr. 30 | Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024 | |
| Apr. 30 | Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2026.
- The group's high margin levels account for strong profits.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -18.47% | 1.06B | B- | ||
| -25.27% | 120M | - | - | |
| -12.28% | 64.19M | - | ||
| +0.27% | 57.13M | - | - | |
| +1.20% | 53.15M | - | - | |
| -7.99% | 50.21M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MDXG Stock
- Ratings MiMedx Group, Inc.
